Literature DB >> 17987650

Group I nonreciprocal inhibition in primary restless legs syndrome.

Cesa Scaglione1, Roberto Vetrugno, Giuseppe Plazzi, Giovanni Rizzo, Federica Provini, Pasquale Montagna, Paolo Martinelli.   

Abstract

Electrophysiological investigations of restless legs syndrome (RLS) have found spinal circuits impinging on motoneurones. We evaluated the H reflex threshold, latency, the Hmax/Mmax ratio, and the short latency autogenic inhibition in 7 patients with RLS and 10 age-matched controls by testing the excitability changes in soleus H reflex Ib interneuron function. A significant reduction in Ib inhibition at 4 (P = 0.043), 5 (P = 0.007), and 6 ms (P = 0.001) of H reflex conditioning interstimulus interval was found in RLS patients. Data support the hypothesis that altered group I nonreciprocal inhibition is implicated in enhancing the spinal circuitry excitability of RLS, and are consistent with the view of an abnormal supraspinal drive to spinal interneurons in RLS. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2008        PMID: 17987650     DOI: 10.1002/mds.21794

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

1.  Ih contributes to increased motoneuron excitability in restless legs syndrome.

Authors:  Dirk Czesnik; James Howells; Michael Bartl; Elisabeth Veiz; Rebecca Ketzler; Olga Kemmet; Arthur S Walters; Claudia Trenkwalder; David Burke; Walter Paulus
Journal:  J Physiol       Date:  2018-11-24       Impact factor: 5.182

2.  What patients do to counteract the symptoms of Willis-Ekbom disease (RLS/WED): Effect of gender and severity of illness.

Authors:  Ravi Gupta; Deepak Goel; Sohaib Ahmed; Minakshi Dhar; Vivekananda Lahan
Journal:  Ann Indian Acad Neurol       Date:  2014-10       Impact factor: 1.383

3.  Impaired Sensorimotor Integration in Restless Legs Syndrome.

Authors:  Yicong Lin; Yijin Wang; Shuqin Zhan; Yan Ding; Yue Hou; Li Wang; Yuping Wang
Journal:  Front Neurol       Date:  2018-07-11       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.